Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.43 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470735 | 0.92 | NTRK1 (0.42) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL610961 | 0.91 | NTRK1 (0.41) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL457722 | 0.91 | NTRK1 (0.41) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL457724 | 0.91 | NTRK1 (0.41) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL458712 | 0.91 | NTRK1 (0.41) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL14722979 | 0.90 | NTRK1 (0.41) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL6128115 | 0.90 | NTRK1 (0.41) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL14723522 | 0.89 | NR1H2 (0.42) | NTRK1F2RNPY5RNR1H2RET | |
| SCHEMBL609161 | 0.88 | AAK1 (0.41) | NTRK1RETDPP4RORC | |
| SCHEMBL470545 | 0.88 | NTRK1 (0.39) | NTRK1F2RNPY5RNR1H2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010103335-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |